Tuesday, 15 September 2015

Report On: Juvenile Macular Degeneration (Stargardt Disease) Industry 2015-2020

This report provides comprehensive information on the therapeutic development for JuvenileMacular Degeneration (Stargardt Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


- The report provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Juvenile Macular Degeneration (Stargardt Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Juvenile Macular Degeneration (Stargardt Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Juvenile Macular Degeneration (Stargardt Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Juvenile Macular Degeneration (Stargardt Disease) Overview 6
Therapeutics Development 7
Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) - Overview 7
Pipeline Products for Juvenile Macular Degeneration (Stargardt Disease) - Comparative Analysis 8
Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics under Development by Companies 9
Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics under Investigation by Universities/Institutes 10
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Juvenile Macular Degeneration (Stargardt Disease) - Products under Development by Companies 13
Juvenile Macular Degeneration (Stargardt Disease) - Products under Investigation by Universities/Institutes 14
Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development 15
Acucela Inc. 15
Alkeus Pharmaceuticals, Inc. 16
Ocata Therapeutics, Inc. 17
Sanofi 18
Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ALK-001 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
echothiophate iodide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30

Request A Sample copy of This Report @ http://www.hexareports.com/sample/46611

emixustat hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Gene Therapy for Stargardt Disease - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MA09-hRPE - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SAR-422459 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule for Stargardt Disease - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
VSM-20R - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Juvenile Macular Degeneration (Stargardt Disease) - Recent Pipeline Updates 40
Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones 53
Featured News & Press Releases 53
May 26, 2015: Ocata Therapeutics Receives Three New U.S. Patents for its RPE Therapy for Macular Degenerative Diseases 53
May 04, 2015: European Medicines Agency Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 53
Mar 31, 2015: Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies 54
Oct 15, 2014: ACT Announces Positive Results from Two Clinical Trials Published in The Lancet Using Differentiated Stem Cell-Derived Retinal Pigment Epithelium (RPE) Cells for the Treatment of Macular Degeneration 54
Sep 25, 2014: Advanced Cell Technology Announces Final Patient Treated in Stargardt's Macular Degeneration Phase 1 Trial in the United Kingdom 55
Jul 17, 2013: ACT Secures Approval from Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials 56
May 16, 2013: ACT Confirms Clinical Trial Participant Shows Improvement In Vision Following Treatment With Human Embryonic Stem Cells 56
Apr 23, 2013: ACT Initiates Higher-Dosage Patient Treatment In European Phase I Study For Macular Degeneration 57
Apr 15, 2013: ACT Treats First Patient With Better Vision In Clinical Trial For Stargardt's Macular Dystrophy 57
Apr 01, 2013: ACT Initiates Treatment Of Higher-dosage Cohort In Clinical Trials For Dry Age-related Macular Degeneration And Stargardt's Macular Dystrophy 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Information:

Ryan Shaw

Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number

1 comment:

  1. It’s a medical condition which may result in blurred or no vision in the center of the visual field. Early on there is no symptoms of this disease. Over time, people experience worsening of vision in one or both eye. There is no better choice than taking consultant for macular degeneration treatment